Xeris Biopharma Q1 2024 Earnings Report
Key Takeaways
Xeris Biopharma reported a 22% increase in total revenue to $40.6 million for Q1 2024 compared to Q1 2023. The growth was primarily driven by Recorlev, Keveyis and Gvoke sales. The company tightened its full-year 2024 revenue guidance to $175 million - $200 million.
Total revenue increased by 22% to $40.6 million compared to Q1 2023.
Gvoke revenue increased by 10% with growing market share, despite an estimated $3 million negative impact from the Change Healthcare cyberattack.
Recorlev revenue increased by 136.7% compared to the same period last year.
Entered into a worldwide license agreement for XeriJect formulation of teprotumumab and an exclusive worldwide agreement with Beta Bionics for a new XeriSol formulation of glucagon.
Xeris Biopharma
Xeris Biopharma
Xeris Biopharma Revenue by Segment
Forward Guidance
The company is tightening full-year 2024 total revenue guidance to $175 million - $200 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income